drugset / Trial / NCT06556108

ALPP CAR-T Cells for ALPP-Positive Advanced Solid Tumors

NCT06556108 ↗

Phase 1/2 Completed 5 enrolled Xinqiao Hospital of Chongqing
NaSingle-groupOpen-labelTreatment

Summary

Alkaline phosphatase (ALP) is a membrane-bound glycoprotein that catalyzes the hydrolysis of phosphates at alkaline pH values. As one of the earliest discovered oncofetal antigens, ALP has emerged as a significant biomarker for various malignant tumors, such as ovarian cancer, breast cancer, trophoblastic tumors, germ cell tumors, endometrial cancer, testicular tumors, cervical intraepithelial neoplasia, and gastrointestinal tumors.

Timeline

Start
2018-01-01
Primary completion
2025-01-30
Completion
2025-07-30

Drugs

EvaluationDrugModalityDoseRoute
Subject ALPP CAR-T cells Cell therapy — —
Background Cyclophosphamide Other / unclassified — —
Background Fludarabine Small molecule — —

Indications